Literature DB >> 32915645

Lower PDL1, PDL2, and AXL Expression on Lung Myeloid Cells Suggests Inflammatory Bias in Smoking and Chronic Obstructive Pulmonary Disease.

Sreelakshmi Vasudevan1,2, Joshua J Vásquez2,3, Wenxuan Chen1,2,3, Brandon Aguilar-Rodriguez2,3, Erene C Niemi1,4, Siyang Zeng1,2, Whitney Tamaki3, Mary C Nakamura1,4, Mehrdad Arjomandi1,2,5.   

Abstract

Lung myeloid cells are important in pulmonary immune homeostasis and in the pathogenesis of chronic obstructive pulmonary disease (COPD). Multiparameter immunophenotypic characterization of these cells is challenging because of their autofluorescence and diversity. We evaluated the immunophenotypic landscape of airway myeloid cells in COPD using time of flight mass cytometry. Cells from BAL, which were obtained from never-smokers (n = 8) and smokers with (n = 20) and without (n = 4) spirometric COPD, were examined using a 44-parameter time of flight mass cytometry panel. Unsupervised cluster analysis was used to identify cellular subtypes that were confirmed by manual gating. We identified major populations of CD68+ and CD68- cells with 22 distinct phenotypic clusters, of which 18 were myeloid cells. We found a higher abundance of putative recruited myeloid cells (CD68+ classical monocytes) in BAL from patients with COPD. CD68+ classical monocyte population had distinct responses to smoking and COPD that were potentially related to their recruitment from the interstitium and vasculature. We demonstrate that BAL cells from smokers and subjects with COPD have lower AXL expression. Also, among subjects with COPD, we report significant differences in the abundance of PDL1high and PDL2high clusters and in the expression of PDL1 and PDL2 across several macrophage subtypes suggesting modulation of inflammatory responses. In addition, several phenotypic differences in BAL cells from subjects with history of COPD exacerbation were identified that could inform potential disease mechanisms. Overall, we report several changes to the immunophenotypic landscape that occur with smoking, COPD, and past exacerbations that are consistent with decreased regulation and increased activation of inflammatory pathways.

Entities:  

Keywords:  COPD; COPD exacerbations; lung immunology; macrophages; mass cytometry

Mesh:

Substances:

Year:  2020        PMID: 32915645      PMCID: PMC7790144          DOI: 10.1165/rcmb.2020-0085OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  31 in total

Review 1.  The chemokine system in diverse forms of macrophage activation and polarization.

Authors:  Alberto Mantovani; Antonio Sica; Silvano Sozzani; Paola Allavena; Annunciata Vecchi; Massimo Locati
Journal:  Trends Immunol       Date:  2004-12       Impact factor: 16.687

2.  Smoking cessation rapidly reduces cell recovery in bronchoalveolar lavage fluid, while alveolar macrophage fluorescence remains high.

Authors:  C M Sköld; J Hed; A Eklund
Journal:  Chest       Date:  1992-04       Impact factor: 9.410

3.  Repeated exposure to ozone increases alveolar macrophage recruitment into asthmatic airways.

Authors:  Mehrdad Arjomandi; Allyson Witten; Emilio Abbritti; Kurt Reintjes; Isabelle Schmidlin; Wenwu Zhai; Colin Solomon; John Balmes
Journal:  Am J Respir Crit Care Med       Date:  2005-06-03       Impact factor: 21.405

Review 4.  Siglec-mediated regulation of immune cell function in disease.

Authors:  Matthew S Macauley; Paul R Crocker; James C Paulson
Journal:  Nat Rev Immunol       Date:  2014-09-19       Impact factor: 53.106

5.  High concentrations of cadmium, cerium and lanthanum in indoor air due to environmental tobacco smoke.

Authors:  Antje Böhlandt; Rudolf Schierl; Juergen Diemer; Christoph Koch; Gabriele Bolte; Mandy Kiranoglu; Hermann Fromme; Dennis Nowak
Journal:  Sci Total Environ       Date:  2011-12-02       Impact factor: 7.963

6.  Loss of CCR2 expression and functional response to monocyte chemotactic protein (MCP-1) during the differentiation of human monocytes: role of secreted MCP-1 in the regulation of the chemotactic response.

Authors:  L Fantuzzi; P Borghi; V Ciolli; G Pavlakis; F Belardelli; S Gessani
Journal:  Blood       Date:  1999-08-01       Impact factor: 22.113

7.  Autophagy induced by AXL receptor tyrosine kinase alleviates acute liver injury via inhibition of NLRP3 inflammasome activation in mice.

Authors:  Jihye Han; Joonbeom Bae; Chang-Yong Choi; Sang-Pil Choi; Hyung-Sik Kang; Eun-Kyeong Jo; Jongsun Park; Young Sik Lee; Hyun-Seuk Moon; Chung-Gyu Park; Myung-Shik Lee; Taehoon Chun
Journal:  Autophagy       Date:  2016-12       Impact factor: 16.016

8.  Reference spirometric values using techniques and equipment that meet ATS recommendations.

Authors:  R O Crapo; A H Morris; R M Gardner
Journal:  Am Rev Respir Dis       Date:  1981-06

9.  Flow Cytometric Analysis of Myeloid Cells in Human Blood, Bronchoalveolar Lavage, and Lung Tissues.

Authors:  Yen-Rei A Yu; Danielle F Hotten; Yuryi Malakhau; Ellen Volker; Andrew J Ghio; Paul W Noble; Monica Kraft; John W Hollingsworth; Michael D Gunn; Robert M Tighe
Journal:  Am J Respir Cell Mol Biol       Date:  2016-01       Impact factor: 6.914

10.  The inducible CXCR3 ligands control plasmacytoid dendritic cell responsiveness to the constitutive chemokine stromal cell-derived factor 1 (SDF-1)/CXCL12.

Authors:  Béatrice Vanbervliet; Nathalie Bendriss-Vermare; Catherine Massacrier; Bernhard Homey; Odette de Bouteiller; Francine Brière; Giorgio Trinchieri; Christophe Caux
Journal:  J Exp Med       Date:  2003-09-01       Impact factor: 14.307

View more
  2 in total

1.  Update in Chronic Obstructive Pulmonary Disease 2020.

Authors:  Andy I Ritchie; Jonathon R Baker; Trisha M Parekh; James P Allinson; Surya P Bhatt; Louise E Donnelly; Gavin C Donaldson
Journal:  Am J Respir Crit Care Med       Date:  2021-07-01       Impact factor: 21.405

Review 2.  Regulation of myeloid-cell activation.

Authors:  Joseph T Greene; Ben F Brian; S Erandika Senevirathne; Tanya S Freedman
Journal:  Curr Opin Immunol       Date:  2021-10-01       Impact factor: 7.486

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.